ILMN · Illumina, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 25, 2024; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Capital expenditures for free cash flow purposes non-GAAP | $39M | Q2 2026 | — |
|
|
|||
| Free cash flow non-GAAP | $412M | Six Months Ended June 28, 2026 | — |
|
|
|||
| Non-GAAP diluted earnings per share non-GAAP | $2.46 | Six Months Ended June 28, 2026 | — |
|
|
|||
| Non-GAAP operating margin non-GAAP | 22.2% | Six Months Ended June 28, 2026 | — |
|
|
|||
| Non-GAAP operating profit non-GAAP | $499M | Six Months Ended June 28, 2026 | — |
| Organic revenue growth (non-GAAP) non-GAAP | 3.9% | Six Months Ended June 28, 2026 | — |
| ROW organic revenue growth (non-GAAP) non-GAAP | 5.8% | Six Months Ended June 28, 2026 | — |
| Cash flow provided by operations | $289M | Q1 2026 | — |
| Depreciation and amortization expense | $69M | Q1 2026 | — |
| Consolidated Constant currency revenue non-GAAP | $4.33B | Year Ended December 28, 2025 | — |
| Constant currency revenue non-GAAP | $4.33B | Year Ended December 28, 2025 | — |
| Core Illumina - Excluding Greater China - Constant currency revenue non-GAAP | $4.09B | Year Ended December 28, 2025 | — |
| Core Illumina Free cash flow non-GAAP | $931M | Year Ended December 28, 2025 | — |
| Ex-China revenue | $4.1B | Fiscal Year 2025 | — |
| Non-GAAP gross profit non-GAAP | $777M | Three Months Ended December 28, 2025 | — |
| Non-GAAP net income non-GAAP | $756M | Year Ended December 28, 2025 | — |
| Non-GAAP other (expense) income, net non-GAAP | -$54M | Year Ended December 28, 2025 | — |
| Non-GAAP R&D expense non-GAAP | $238M | Three Months Ended December 28, 2025 | — |
| Non-GAAP SG&A expense non-GAAP | $264M | Three Months Ended December 28, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ILMN
this stock
Illumina, Inc.
|
$34.38B | +64.4% | -0.7% | 42.5 | 6.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$230.05B | +7.4% | +14.5% | 33.5 | 1.3% |
|
DHR
Danaher Corp /De/
|
$151.51B | -5.6% | +8.5% | 38.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$48.82B | +42.4% | -2.8% | — | 3.0% |
|
IQV
Iqvia Holdings Inc.
|
$43.79B | +16.1% | +41.6% | 32.6 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 25, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ILMN | -1.7% | +5.1% | +73.5% | +5.1% | +64.4% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -2.2% | +2.1% | +60.0% | +2.1% | +51.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.